Streetbeat News

Stock Prices

DLHC

DLH Holdings (NASDAQ:DLHC) reported Q3 2024 earnings per share of $0.08, missing the analyst consensus estimate of $0.14 by 42.86%. The company also reported quarterly sales of $100.694 million, which missed the estimate of $103.000 million by 2.24%. This represents a 1.51% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 9:05 pm

CNMD

Conmed (NYSE:CNMD) reported Q2 2024 adjusted EPS of $0.98, beating the estimate of $0.91. However, sales of $332.097 million missed the estimate of $332.325 million. Sales increased by 4.55% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 9:04 pm

UDMY

Udemy shares are trading lower after the company reported mixed Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 9:04 pm

PTVE

Pactiv Evergreen (NASDAQ:PTVE) reported Q2 2024 adjusted EPS of $0.17, missing the analyst estimate of $0.25 by 32%. Sales were $1.338 billion, also missing the estimate of $1.362 billion by 1.75%. This represents a 6.17% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 9:03 pm

EOLS

Evolus shares are trading higher following the company's Q2 financial results announcement.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 9:03 pm

WDC

Western Digital Corp (NASDAQ:WDC) reported strong Q4 results, beating analyst estimates with earnings of $1.44 per share and sales of $3.76 billion. Despite the positive results, shares are down 4.55% after-hours. The company provided an optimistic Q1 outlook, with earnings and revenue guidance above estimates.

Portfolio Pulse from Erica Kollmann

July 31, 2024 | 9:02 pm

LAB

Standard BioTools shares are trading lower following the company's Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 9:02 pm

LTBR

Lightbridge (NASDAQ:LTBR) reported a Q2 EPS loss of $(0.17), a 21.43% decrease from the $(0.14) loss per share in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 9:02 pm

SAVA

Cassava Sciences, Inc. (NASDAQ:SAVA) saw a significant stock price increase after announcing an extension of its open-label extension trials for its Alzheimer's treatment, simufilam. The extension aims to provide continuous treatment for patients and gather more long-term data. The company is also conducting two major Phase 3 studies, with results expected in 2024 and 2025.

Portfolio Pulse from Vaishali Prayag

July 31, 2024 | 9:01 pm

OLO

Olo shares are trading higher after the company reported better-than-expected Q2 sales results.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 9:01 pm